About DBV

Dedicated to Improving the Lives of Patients with Food Allergies and Other Immunological Diseases

Learn More

Our Pipeline

We are exploring the broad potential applications of the Viaskin™ Platform

Learn More

Our Science

The Viaskin™ patch is our novel approach to EPIT™

Learn More

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.

We are on a journey to advance epicutaneous immunotherapy, using our innovative technology platform, Viaskin™

We are exploring the first epicutaneous immunotherapy (EPIT™) treatment for peanut allergy

We plan to explore a potential new class of immunotherapy to transform the lives of people with unmet medical needs

Our Pipeline

DBV’s robust development program includes ongoing clinical trials. Viaskin’s potential to re-educate the immune system makes it a promising approach beyond food allergies.

View all

Michele Robertson DBV Chief Legal Officer

Viaskin™ Peanut (DBV712)

Peanut Allergy

Comprehensive clinical research program in place, including Phase 3, long-term studies

Learn more

Viaskin™ Milk (DBV135) Cow’s Milk Allergy

Viaskin™ Milk (DBV135)

Cow’s Milk Allergy

Completed a Phase 1/2 trial to study safety and efficacy in pediatric and adolescent patients

Learn more

Viaskin™ Milk (DBV135)  Cow’s Milk-induced EoE

Viaskin™ Milk (DBV135)

Cow’s Milk-Induced EoE

Completed a Phase 2a study sponsored by the Children’s Hospital of Philadelphia (CHOP)

Learn more

Our Science

Our Science

DBV’s Approach to Re-Educating the Immune System

Our novel Viaskin patch is based on investigational EPIT. This potential new class of immunotherapy is designed to induce an immune response by introducing minimal amounts of antigen to the skin.

Food Allergies Are a Global Health Issue

We are developing the Viaskin technology platform to help improve the lives of patients diagnosed with peanut and other food allergies.

An estimated 8% of children in the U.S., or approximately 2 children in every classroom, have a food allergy

Peanut allergy is one of the most common food allergies, and can cause severe, potentially fatal, allergic reactions, as well as anaphylaxis.

In Europe, about 17 million people are affected by food allergies, including 3.5 million under the age of 25.

Research suggests that only about 20% of people with peanut allergy are expected to outgrow it during their lifetime

Between 1994 and 2005 Australia experienced a 350% increase in hospital admissions for food-related anaphylaxis episodes, mostly in children under the age of five

News & Resources

To stay up to date on DBV news and events, please click here.


News • 10/18/2021

Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2021

Download PDF

Resource • 10/05/2021

DBV Corporate Presentation

Download PDF